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ABSTRACT: Human islet amyloid polypeptide (hIAPP or
amylin) is a polypeptide hormone produced in the pancreatic
β-cells that plays a role in glycemic control. hIAPP is deficient
in type 1 and type 2 diabetes and is a promising adjunct to
insulin therapy. However, hIAPP rapidly forms amyloid, and
its strong tendency to aggregate limits its usefulness. The
process of hIAPP amyloid formation is toxic to cultured β-cells
and islets, and islet amyloid formation in vivo has been linked to β-cell death and islet graft failure. An analogue of hIAPP with
a weakened tendency to aggregate, denoted pramlintide (PM), has been approved for clinical applications, but suffers from poor
solubility, particularly at physiological pH, and its unfavorable solubility profile prevents coformulation with insulin. We describe
a strategy for rationally designing analogues of hIAPP with improved properties; key proline mutations are combined with
substitutions that increase the net charge of the molecule. An H18R/G24P/I26P triple mutant and an H18R/A25P/S28P/S29P
quadruple mutant are significantly more soluble at neutral pH than hIAPP or PM. They are nonamyloidogenic and are not
toxic to rat INS β-cells. The approach is not limited to these examples; additional analogues can be designed using this strategy.
To illustrate this point, we show that an S20R/G24P/I26P triple mutant and an H18R/I26P double mutant are
nonamyloidogenic and significantly more soluble than human IAPP or PM. These analogues and second-generation derivatives
are potential candidates for the coformulation of IAPP with insulin and other polypeptides.
Insulin therapy is the most widely used treatment fordiabetes. Despite improvements in insulin therapy over the
past few decades, the goal of achieving complete glycemic
control in diabetic patients has still not been achieved.
Postprandial hyperglycemia persists in diabetes, even with
aggressive insulin therapy, due, in part, to the imbalance of
secreted hormones that normally work together to achieve
normal glucose homeostasis.1
Human islet amyloid polypeptide (hIAPP or amylin) is a
neuropancreatic hormone produced in the pancreatic β-cells.
The polypeptide is stored in the insulin secretory granule
and cosecreted with insulin.2,3 Mature hIAPP is 37 residues in
length and contains an amidated C-terminus and a disulfide
bond between Cys-2 and Cys-7 (Figure 1). hIAPP normally
complements insulin by suppressing postprandial glucagon
secretion, helping to regulate the rate of gastric emptying,
and inducing satiety.4−7 The polypeptide forms amyloid in
the pancreatic islets of Langerhans in type 2 diabetes by an
unknown mechanism. hIAPP amyloid deposits are associated
with reduced β-cell mass, and islet amyloidosis is believed
to contribute to type 2 diabetes.2,8−11 Islet amyloidosis also
contributes to the failure of islet transplantation, and recent
work has shown that prevention of islet amyloid formation
enhances graft survival.12,13 hIAPP also aggregates aggressively
in vitro and is one of the most aggregation prone naturally
occurring sequences known.
hIAPP is deficient in both type 1 and type 2 diabetes
patients14−16 and is a promising adjunct to insulin therapy.
However, clinical use of hIAPP is not practical because of its
aggressive tendency to aggregate in vitro, leading to difficulties
in formulation and storage, and because some hIAPP aggregates
are toxic to β-cells.
Not all species form islet amyloid, and the ability to do so
correlates with the primary sequence of IAPP. A number of non-
amyloidgenic IAPP variants contain multiple proline substitu-
tions, a well-known breaker of β-structure within the segment
of residues 20−29.17,18 Early work led to the suggestion that the
sequence in this region controls the amyloidogenicity of the
polypeptide. The situation has subsequently been shown to
be more complex. Variations outside of the segment of residues
20−29 can influence significantly the amyloidogenicity of
IAPP, and multiple proline substitutions in other segments of
the molecule can inhibit amyloid formation.19,20 In addition, the
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charge state of residue 18 and the charge state of the N-terminus
play an important role in modifying the tendency to aggregate
and form amyloid.21 Nevertheless, substitutions within the
region of residues 20−29 are very important in determining the
amyloidogencity of IAPP.20,22−24 Analysis of the relationship
between sequence and amyloidogenicity has led to the develop-
ment of IAPP analogues, based upon rat IAPP (rIAPP), that are
less prone to aggregation than hIAPP.
rIAPP differs from the human polypeptide at six positions,
with five of the substitutions, including three prolines, found
between residues 20 and 29. rIAPP is not toxic, does not form
amyloid, and is more soluble than hIAPP, due in part to
the three prolines at positions 25, 28, and 29.18,25 These residues
are Ala, Ser, and Ser, respectively, in the human polypeptide
(Figure 1). The sequence differences between rat and human
IAPP have been exploited to develop a more soluble analogue of
hIAPP, pramlintide (PM, also known as Symlin), that has been
clinically approved as an adjunct to insulin therapy, in which
residues 25, 28, and 29 of hIAPP are substituted with proline
(Figure 1). These substitutions render the human peptide
nonamyloidgenic under typical conditions. Clinical studies show
that PM retains the activity of hIAPP, and the addition of PM
to insulin therapy improves postprandial glycemic control in
patients with type 1 and type 2 diabetes.1,26−30
PM still has solubility issues, particularly at physiological
pH. PM is more soluble at acidic pH where the N-terminus
and His-18 will be fully protonated and is formulated under
these conditions, while insulin is formulated at near neutral pH.
This prevents the coformulation of insulin and PM, leading to
increased cost in combination therapies and potentially reducing
patient compliance, due to the need for multiple injections.
There is also interest in the coformulation of IAPP or PM with
other proteins, and IAPP analogues with improved solubility
should be useful in this context, as well.31−33
Here, we describe an approach for rationally designing
analogues of hIAPP with improved solubility that involves
minimal substitutions. The strategy relies on mutating select
residues to proline and making an additional substitution to
increase the net charge of the molecule. We demonstrate the
approach with an H18R/G24P/I26P triple mutant (TM-a) and
an H18R/Ala-25/Ser-28/Ser-29 quadruple mutant (QM). Both
are significantly more soluble than hIAPP or PM, and both are
nonamyloidogenic and are not toxic to INS-1 β-cells. The approach
is not limited to these two cases, and additional analogues can
be designed using this strategy (Figure 1). We illustrate this
point with an S20R/G24P/I26P triple mutant (TM-b) and an
H18R/I26P double mutant (DM).
■ MATERIALS AND METHODS
Peptide Synthesis. All peptides were synthesized on a
0.1 mmol scale using a CEM microwave peptide synthesizer.
9-Fluorenylmethoxycarbonyl (Fmoc) chemistry was utilized.
5-(4′-Fmoc-aminomethyl-3′,5-dimethoxyphenol) valeric acid
(PAL-PEG) resin was used to afford an amidated C-terminus.
For hIAPP, TM-a, TM-b, and DM, Fmoc-protected pseudopro-
line (oxazolidine) dipeptide derivatives were incorporated to
improve the yield as previously described.34 For PM and QM,
only Fmoc-Ala-Thr(ΨMe, Mepro)-OH and Fmoc-Leu-Ser-
(ΨMe, Mepro)-OH were utilized. Standard Fmoc reaction cycles
were used as previously described.35 The first residue attached
to the resin, all β-branched residues, and all pseudoproline
dipeptide derivatives were double-coupled. The peptides were
cleaved from the resin using standard trifluoroacetic acid (TFA)
methods.
Oxidation and Purification of Peptides. Crude peptides
collected after cleavage were dissolved in 20% (v/v) acetic acid
and lyophilized. This step was repeated several times before
oxidation and purification to improve the solubility of the
peptides. The peptides were oxidized in 100% dimethyl sulfoxide
at room temperature to form the disulfide bond and then
purified via reverse-phase high-performance liquid chromatog-
raphy (RP-HPLC) using a Vydac C18 preparative column.36 The
masses of the pure peptides was confirmed by matrix-assisted
laser desorption ionization time-of-flight mass spectrometry:
hIAPP, expected 3903.6, observed 3904.6; PM, expected 3949.3,
observed 3949.2; QM, expected 3969.4, observed 3968.1; TM-a,
expected 3946.9, observed 3945.7; TM-b, expected 3997.4,
observed, 3997.1; DM, expected 3907.3, observed, 3908.1.
Sample Preparation. Each peptide was dissolved in 100%
hexafluoroisoproponal (HFIP) to make a 1.6 mM stock solution.
Stock solutions were filtered using a 0.45 μM Acrodisc syringe
filter with a GHP membrane, and the required amount of
peptide was lyophilized overnight to remove HFIP. Dry peptide
was dissolved into the appropriate buffer for the fluorescence
assays.
Figure 1. Sequences of human IAPP (hIAPP), rat IAPP (rIAPP), pramlintide (PM), H18R pramlintide (QM), H18R/G24P/I26P IAPP (TM-a),
S20R/G24P/I26P IAPP (TM-b), and H18R/I26P IAPP (DM). Each peptide contains a disulfide bond connecting Cys-2 and Cys-7 and an amidated
C-terminus. Residues that differ from those of human IAPP are colored red.
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Fluorescence Assays. Thioflavin-T binding assays, con-
ducted without stirring at 25 °C, were utilized to monitor
amyloid formation kinetics. Fluorescence measurements were
performed using a Beckman Coulter DTX 880 plate reader
with a multimode detector using an excitation wavelength of
430 nm and an emission wavelength of 485 nm. Samples were
prepared by dissolving the dry peptide into Tris-HCl buffer and
a thioflavin-T solution immediately before the measurement.
The final concentrations were 16 μM hIAPP or 160 μM
analogue (each one) and 32 μM thioflavin-T in 20 mM Tris-
HCl (pH 7.4).
Solubility Measurements. Dry peptides were dissolved
in PBS buffer containing 10 mM PO4
3−, 137 mM NaCl, and
2.7 mM KCl (pH 7.4) at different initial concentrations and
incubated for 7 days at 25 °C without being stirred. Each sample
was then centrifuged using a Beckman Coulter Microfuge 22R
centrifuge at 24 °C for 20 min. The relative centrifugal force
used was 1.75 × 104g. The solubility of each sample was
approximated by measuring the absorbance of the correspond-
ing supernatant at 280 nm measured using a Beckman Coulter
DU 730 UV/vis spectrophotometer. All of the peptides contain
a single Tyr, three Phe residues, and a disulfide bond and no
Trp; thus, their extinction coefficients at 280 nm are identical.
Liquid Chromatography−Mass Spectroscopy (LC−MS)
Experiments. Samples were prepared by dissolving insulin,
at an equimolar ratio, with either PM, DM, or TM-a in PBS
buffer (pH 7.4) at an initial concentration of 500 μM. Aliquots
were removed at time zero (control). Additional aliquots were
removed after incubation for 24 h and centrifuged (17500g
for 20 min). Aliquots were immediately frozen with liquid
nitrogen and lyophilized. LC−UV−MS measurements were
taken by redissolving the samples and immediately injecting
them. Samples were analyzed using an Agilent 1260 HPLC
instrument and an Agilent G6224A TOF mass spectrometer.
The HPLC method used a Kinetex C18 column [100 Å,
2.6 μm, 100 mm × 2.1 mm (Phenomenex)] at 35 °C and a flow
rate of 0.60 mL/min. The HPLC solvents were (A) H2O [0.1%
(v/v) acetic acid and 0.1% (v/v) TFA] and (B) CH3CN [0.1%
(v/v) acetic acid and 0.1% (v/v) TFA]. The HPLC solvent
gradient consisted of the following: 10% B from 0 to 1.5 min,
10 to 50% B from 1.5 to 21.5 min, and 50 to 95% B from
21.5 to 31.5. Mass spectra were acquired in the range of m/z
300−3200 with internal calibration using five standards in
profile mode at 5 Hz. Electrospray ionization in the positive
mode was used: cap voltage of 4000 V, gas temperature of
325 °C, drying gas of 12 L/min, nebulizer of 55 psi, and
fragmentor voltage of 200 V.
UV chromatograms were acquired with a diode array detector
(DAD) operating with a 10 Hz acquisition rate and a 2 nm
bandwidth in the range of 205−500 nm. The absorbance was
recorded at 215 ± 8 and 280 ± 8 nm with a 500 ± 50 nm
reference wavelength to obtain integrated UV areas. ESI+, TIC
(total ion current) mass chromatograms were integrated, and
averaged mass spectra were acquired from the integrated peaks
with background subtraction. The mass spectra of the target
peptides were observed in predominantly the +3 and +4 charge
states. The resolution of the mass spectrometer in the described
state and in this m/z range is ∼13000. This resolution allows the
isotopic distribution of the peptide m/z peaks in these charge
states to be fully resolved. Mass spectra were deconvoluted
using the Agilent Resolved Isotope Deconvolution algorithm.
The monoisotopic, neutral masses were determined with an
accuracy of ±10 ppm. The extracted ion chromatograms (EIC)
were used with the two most intense m/z ions from the +3 and
+4 charge states for relative quantitation from the mass
chromatograms.
Transmission Electron Microscopy (TEM). TEM images
were collected at the Life Science Microscopy Center at the
State University of New York at Stony Brook. Aliquots (15 μL)
of the samples used for fluorescence assays were removed at
the end of each kinetic experiment, blotted on a carbon-coated
200-mesh copper grid for 1 min, and then negatively stained
with saturated uranyl acetate for 1 min.
Circular Dichroism (CD). Far-UV CD experiments were
performed on an Applied Photophysics Chirascan CD spectro-
photometer at 25 °C. Aliquots from the kinetic experiments
were removed at the end of each experiment, and the spectra
were recorded as the average of three repeats over a range of
190−260 nm, at 1 nm intervals. A 0.1 cm quartz cuvette was
used, and a background spectrum was subtracted from the data.
Cell Culture. Transformed rat insulinoma-1 (INS-1)
pancreatic β-cells were grown in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS), 11 mM glucose, 10 mM
Hepes, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μM
β-mercaptoethanol, 100 units/mL penicillin, and 100 units/mL
streptomycin. Cells were maintained at 37 °C under 5% CO2.
AlamarBlue Cell Viability Assays. Cytotoxicity was
measured by AlamarBlue reduction assays. INS-1 β-cells were
seeded at a density of 30000 cells/well in 96-well plates and
cultured for 24 h prior to being stimulated with wild-type
hIAPP and mutant IAPP peptides. Peptides dissolved in RPMI
were added directly to cells and incubated on cells for 24 and
48 h. AlamarBlue was diluted 10-fold in culture media and
incubated on cells for an additional 5 h at 37 °C. The fluore-
scence (excitation at 530 nm and emission at 590 nm) was
measured on a Beckman Coulter DTX880 fluorescent
plate reader. Values were calculated relative to those of control
cells treated with buffer only. All values represent means ± the
standard error of the mean (n = 4).
■ RESULTS AND DISCUSSION
Design of Soluble Analogues. The rate of amyloid
formation by hIAPP is strongly dependent on pH and is
significantly faster above neutral pH, because of changes in the
ionization state of the N-terminus and His-18.21,37−39 PM and
hIAPP both contain a His residue at position 18, while rIAPP
contains an Arg. These observations led us to suspect that the
solubility of PM could be significantly increased by ensuring
that residue 18 remains positively charged in the pH range of
interest. The two choices for substitution among the genetically
encoded amino acids are Lys and Arg. Either would accomplish
this goal; however, the Arg replacement is found in a number of
IAPP sequences, while the Lys replacement is not. In addition,
the amino group in Lys is generally more reactive than the
guanidino group of Arg because of its lower pKa; thus, we chose
to replace His-18 in the human peptide with Arg to generate
the quadruple mutant, H18R/A25P/S28P/S29P IAPP, denoted
QM. This mutant can also be viewed as an H18R mutant of
pramlintide.
It is natural to inquire if three proline substitutions are
required and if the proline substitutions need to be located at
positions 25, 28, and 29; thus, we designed a second analogue
that contains only two prolines in addition to the H18R sub-
stitution. A single proline mutation at position 24 or 26 of hIAPP
weakens the tendency of the peptide to aggregate and converts
the peptide into a moderately effective inhibitor of amyloid
Biochemistry Article
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formation by wild-type hIAPP.22,40 The motivation for originally
choosing these sites was that substitutions with proline were
shown to have large effects on amyloid formation by a set of
10-residue fragments of hIAPP.41 However, each of the single-
proline mutants of hIAPP still forms nonamyloid aggregates
at neutral pH, even at low concentrations; thus, we prepared an
analogue (TM-a) in which both residues 24 and 26 were
mutated to proline and which included the H18R mutation.
The Analogues Do Not Form Amyloid in a Homoge-
nous Solution. We first tested the propensity of the different
analogues to form amyloid at pH 7.4 using thioflavin-T
fluorescence assays and transmission electron microscopy
(TEM). Thioflavin-T is a small dye that undergoes an increase
in quantum yield upon binding to amyloid fibrils and provides
a convenient probe for monitoring the kinetics of amyloid
formation. The dye does not perturb the kinetics of hIAPP
amyloid formation under the conditions used here. Amyloid
formation follows a sigmoidal time course consisting of a lag
phase, in which few or no fibrils are formed, followed by a
growth phase and then a saturation phase in which amyloid
fibrils are in equilibrium with the soluble peptide. Amyloid
formation by hIAPP reached the saturation phase within 40 h
under the conditions used here, while none of the analogues
tested (PM, TM-a, and QM) formed any detectable amyloid
during the time course of the experiments (∼140 h) as indicated
by flat fluorescence curves and by TEM, even though they
were examined at a concentration 10-fold higher than that of
hIAPP (Figure 2). The thioflavin-T fluorescence signal derives
from the fibril-bound dye, and the intensity is highly dependent
on how well the dye binds; hence, thioflavin-T studies can
sometimes be misleading.42 Therefore, we conducted TEM
measurements of the samples collected at the end of each
kinetic experiment. TEM images of hIAPP showed typical
Figure 2. Thioflavin-T fluorescence assays of hIAPP, TM-a, QM, and
PM: blue for hIAPP, black for TM-a, red for QM, and green for PM.
The black, red, and green curves overlap. The experiments were
conducted in 20 mM Tris-HCl (pH 7.4), without stirring at 25 °C.
The concentration of hIAPP was 16 μM. The concentration of the
other peptides was 160 μM.
Figure 3. TEM images of (A) hIAPP, (B) TM-a, (C) QM, and (D) PM recorded from samples that were collected at the end of the kinetic
experiments shown in Figure 2. Scale bars are 100 nm.
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amyloid fibril morphology, while no fibrils were found in the
TEM images of samples of the three analogues (PM, TM-a, and
QM) (Figure 3).
The Analogues Are Significantly More Soluble Than
PM at Neutral pH. We next compared the apparent
solubilities of PM, TM-a, and QM at pH 7.4. Each peptide
was incubated in PBS buffer containing 10 mM PO4
3−, 137 mM
NaCl, and 2.7 mM KCl for 7 days at three different initial
concentrations (100 μM, 500 μM, and 1 mM), and the solution
was then centrifuged. The apparent solubility of each sample
was approximated by the absorbance of the supernatant
measured at 280 nm. The extinction coefficients of all of the
polypeptides are identical at 280 nm because they contain the
same aromatic residues and each contains a disulfide bond;
thus, the absorbance of the supernatant is a direct readout of
the relative solubility of the different samples. A sample of
hIAPP, prepared at an initial concentration of 1 mM, was used
as a control. At 100 μM, there were detectable differences in the
amount of peptide in the soluble fraction. The supernatant of
the QM sample had an absorbance, 0.16, higher than that of
TM-a (0.10) or PM (0.11) (Figure 4). At higher concentrations
(500 μM and 1 mM), the amount of peptide remaining in
solution was significantly higher for both analogues than
for PM. At 1 mM, the absorbances of the soluble fractions
of TM-a and QM were 1.2 and 1.3, respectively, while the
value for the PM sample was only 0.35. In comparison, the
absorbance of the supernatant of the 1 mM hIAPP sample was
just 0.11 (Figure 4). For the samples prepared at an initial
concentration of 500 μM, the absorbances of the supernatants
of the TM-a and QM solutions were 0.61 and 0.72, res-
pectively, and both were significantly higher than that of PM
(0.33) (Figure 4).
Figure 4. Comparison of the apparent solubilities of TM-a, QM, PM,
and hIAPP. The apparent solubility in PBS buffer at pH 7.4 is re-
presented by the absorbance at 280 nm and was measured after 7 days.
(A) Amount of peptide remaining in the supernatant of samples of
TM-a (black), QM (red), PM (green), and hIAPP (blue) prepared at
an initial concentration of 1 mM. (B) Amount of peptide remaining in
the supernatant of samples of TM-a, QM, and PM measured for
different initial concentrations after incubation for 7 days. The same
color coding is used as in panel A. The absorbance was measured after
centrifugation at 24 °C for 20 min at 1.75 × 104g.
Figure 5. hIAPP is toxic to INS-1 β-cells, but TM-a and QM are not. (A and B) Comparison of cell toxicity induced by hIAPP, TM-a and QM at a
peptide concentration of 21 μM. (A) Cell viability measured after incubation of cells with the peptides for 24 h. (B) Cell viability measured after
incubation of cells with the peptides for 48 h. (C and D) Comparison of cell toxicity induced by the three peptides at 42 μM. (C) Cell viability
measured after incubation of cells with the peptides for 24 h. (D) Cell viability measured after incubation of cells with the peptides for 48 h. Cell
viability was assessed using AlamarBlue reduction assays. Error bars represent the standard deviation determined from four repeated measurements.
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Neither TM-a nor QM Is Toxic to β-Cells. We tested the
effects of the analogues on cell viability using rat INS-1 β-cells,
a pancreatic cell line that is commonly employed in studies of
hIAPP toxicity. Cell viability was monitored by AlamarBlue
assays for peptide samples at 21 and 42 μM. hIAPP was used as
a positive control. Incubating INS-1 β-cells with 21 μM hIAPP
led to clearly detectable toxicity; cell viability was reduced to
62 ± 4% relative to that of the medium alone control after
incubation for 24 h and to 54 ± 5% after incubation for 48 h.
In contrast, incubation of cells with either TM-a or QM at
21 μM barely decreased cell viability (Figure 5). Increasing the
hIAPP concentration to 42 μM resulted in even more signifi-
cant effects; cell viability was reduced to only 14 ± 9% after
incubation for 24 h and 9 ± 9% after incubation for 48 h.
In striking contrast, no obvious cytotoxicity was observed for
TM-a or QM at 42 μM (Figure 5). These results demonstrate
that, unlike hIAPP, TM-a and QM are not toxic to cells at the
concentrations examined.
The Strategy Can Be Extended To Include Charged
Substitutions at Different Sites. We wanted to test if a
charge substitution at a different site would also lead to an
enhanced solubility and reduced amyloidogenicity. We chose
to target Ser-20. Substitution of a glycine at this site leads to
accelerated amyloid formation, while replacement with a Lys
has been shown to slow but not prevent amyloid formation.43
We prepared a S20R/G24P/I26P triple mutant (TM-b)
and tested both its ability to form amyloid and its apparent
solubility at neutral pH. Thioflavin-T fluorescence experiments
and TEM confirmed that TM-b did not form amyloid fibrils
during the time course of the experiments, even at a peptide
concentration of 160 μM (Figure 6). We then compared the
apparent solubility of TM-b with PM and TM-a at pH 7.4 using
the same method described above (Figure 7). TM-b was more
soluble than PM and TM-a. The absorbances of the soluble
fractions of samples of TM-b, TM-a, and PM prepared at an
initial concentration of 100 μM were 0.16, 0.10, and 0.11,
respectively. Examination of samples prepared at higher initial
concentrations revealed that TM-b was much more soluble
than PM and somewhat more soluble than TM-a. We tested
samples prepared at initial concentrations of 500 μM and
1 mM. The absorbances of the supernatants of samples of
TM-b prepared at initial concentrations of 500 μM and 1 mM
were 0.79 and 1.5, respectively, while the values for PM were
0.33 and 0.35, respectively.
Multiple Proline Substitutions Are Not Required To
Design Soluble Analogues. Single-proline substitutions have
been reported to reduce the amyloidgenicity of hIAPP.22 To
test if multiple proline substitutions together with the charged
mutations are required to improve the solubility at neutral pH,
we tested an H18R/I26P double mutant of hIAPP (DM). This
peptide did not form amyloid during the time course of the
experiments, as demonstrated by a flat thioflavin-T fluorescence
curve and by TEM (Figure 8). DM was more soluble at neutral
pH than PM, even though this peptide has only one proline
substitution, while PM has three (Figure 9). The absorbances
of the soluble fractions of 1 mM, 500 μM, and 100 μM samples
of DM measured after incubation for 1 week were 1.2 for the
1 mM sample, 0.67 for the 500 μM sample, and 0.10 for the
100 μM sample.
Designed Analogues Are More Soluble Than Pramlin-
tide in the Presence of Insulin.We examined a subset of the
analogues in the presence of insulin to test if they are more
soluble than PM when insulin is present. We chose TM-a and
DM for comparison to PM, because TM-a and DM differ from
each other only at position 24, which is a proline in TM-a.
Comparison of the two analogues, thus, tests if multiple Pro sub-
stitutions are required for increased solubility in the presence
of insulin. The three polypeptides were individually incubated
with equimolar insulin at an initial concentration of 500 μM
in PBS buffer containing 10 mM PO4
3−, 137 mM NaCl, and
2.7 mM KCl at pH 7.4, and the amount of each IAPP analogue
remaining in solution after 24 h was analyzed. Samples were
centrifuged and aliquots of the supernatant analyzed by LC−MS.
Figure 6. TM-b does not form amyloid, even after incubation for 140 h. (A) Thioflavin-T fluorescence assays. The kinetic experiment was conducted
in 20 mM Tris-HCl (pH 7.4), without stirring at 25 °C. The concentration of TM-b was 160 μM. (B) TEM image of a sample collected at the end of
the experiment shown in panel A. The scale bar is 100 nm.
Figure 7. Comparison of the apparent solubility of samples of TM-a,
TM-b, and PM prepared at different initial concentrations. The
apparent solubility of the peptides in PBS buffer at pH 7.4 is
represented by the absorbance at 280 nm and was measured after
incubation for 7 days: black for TM-a, red for TM-b, and green for PM.
The absorbance was measured after centrifugation at 24 °C for 20 min
at 1.75 × 104g.
Biochemistry Article
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Insulin could be separated from the analogues by LC
(Supporting Information), allowing quantification of the amount
of each IAPP analogue remaining in solution. The amount of
PM in the soluble fraction was notably reduced after 24 h, with
more than 37% of the material having been lost, as judged by the
absorbance at 280 nm, or by the extracted ion chromatography
(EIC) peak intensity (Supporting Information). The two
designed analogues were more soluble than PM in the presence
of insulin, and considerably less material was lost to the insoluble
fraction (<15% for TM-a and <17% for DM). Any difference
between the two designed analogues was modest, as judged
by the absorbance of the samples, indicating that a single,
strategically placed, proline together with a charge substitution is
capable of generating an analogue that has improved solubility in
the presence of insulin.
■ CONCLUSIONS
We have developed a simple strategy for designing non-
amyloidgenic, nontoxic analogues of hIAPP with solubility at
neutral pH significantly better than that of PM. The strategy
includes a minimum combination of mutations that increases
the net charge of the peptide with single or multiple proline
substitutions. Our results demonstrate that the approach is not
limited to a specific site and there is no strict requirement for
the number of proline substitutions. In this case, we have
localized the proline substitutions within the region of residues
20−29; however, it is known that multiple proline substitutions
outside this segment can reduce amyloidogenicity, and thus,
the approach may be even more general.19 It is likely that
N-methylated amino acids could also be used, because they,
like proline, are β-sheet breakers.44,45 Nongenetically encoded
amino acids such as ornithine could likely be used instead of
Lys or Arg. Of course using just the genetically encoded amino
acids facilities peptide production by recombinant means.
Analogues such as the ones described here, and next-generation
variants, are potential adjuncts to insulin therapy that will allow
coformulation with insulin.
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LC chromatographs from LC−MS measurements of mixtures of
insulin with PM, TM-a, and DM recorded for freshly dissolved
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Figure 8. DM does not form amyloid, even after incubation for 140 h. (A) Thioflavin-T fluorescence assays. The kinetic experiment was conducted
in 20 mM Tris-HCl (pH 7.4), without stirring at 25 °C. The concentration of DM was 160 μM. (B) TEM image of a sample collected at the end of
the experiments shown in panel A. The scale bar is 100 nm.
Figure 9. Comparison of the apparent solubilities of samples of TM-a,
TM-b, PM, and DM prepared at different initial concentrations. The
apparent solubility of the peptides in PBS buffer at pH 7.4 is re-
presented by the absorbance at 280 nm and was measured after 7 days:
black for TM-a, red for TM-b, green for PM, and yellow for DM. The
absorbance was measured after centrifugation at 24 °C for 20 min at
1.75 × 104g.
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phase high-performance liquid chromatography; TEM, trans-
mission electron microscopy; TM-a, H18R/G24P/I26P triple
mutant; TM-b, S20R/G24P/I26P triple mutant.
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